Home / Products / Polyclonal antibody /

FGF-23 Polyclonal Antibody

Product code: YP-Ab-15909
Promotional price:

Product introduction

Reactive species
Human;Mouse;Rat
Applications
WB;IF;ELISA
Antibody type
Polyclonal Antibody
Gene Name
FGF23
Protein name
Fibroblast growth factor 23
Dalton(DA)
27kD
Immunogen
The antiserum was produced against synthesized peptide derived from human FGF23. AA range:151-200
Specificity
FGF-23 Polyclonal Antibody detects endogenous levels of FGF-23 protein.
Constitute
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Source
Polyclonal, Rabbit,IgG
Dilution rate
Western Blot: 1/500 - 1/2000. IHC-p: 1:100-300 ELISA: 1/20000. IF 1:100-300 Not yet tested in other applications.
Purification process
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration
1 mg/ml
Stockpile
-20°C/1 year
Other name
FGF23; HYPF; Fibroblast growth factor 23; FGF-23; Phosphatonin; Tumor-derived hypophosphatemia-inducing factor
Background
This gene encodes a member of the fibroblast growth factor family of proteins, which possess broad mitogenic and cell survival activities and are involved in a variety of biological processes. The product of this gene regulates phosphate homeostasis and transport in the kidney. The full-length, functional protein may be deactivated via cleavage into N-terminal and C-terminal chains. Mutation of this cleavage site causes autosomal dominant hypophosphatemic rickets (ADHR). Mutations in this gene are also associated with hyperphosphatemic familial tumoral calcinosis (HFTC). [provided by RefSeq, Feb 2013],
Function
disease:Defects in FGF23 are a cause of hyperphosphatemic familial tumoral calcinosis (HFTC) [MIM:211900]. HFTC is a severe autosomal recessive metabolic disorder that manifests with hyperphosphatemia and massive calcium deposits in the skin and subcutaneous tissues.,disease:Defects in FGF23 are the cause of autosomal dominant hypophosphataemic rickets (ADHR) [MIM:193100]. ADHR is characterized by low serum phosphorus concentrations, rickets, osteomalacia, leg deformities, short stature, bone pain and dental abscesses.,PTM:After secretion it is processed into a N-terminal fragment and a C-terminal fragment. The processing is effected by the proprotein convertases.,similarity:Belongs to the heparin-binding growth factors family.,

Open

Product Details

Customer data and reviews (0)

Fold content

Citation

Fold content

Experimental scheme

Fold content
>